Antibody that binds domain 2 of ICAM-1 and methods of treatment
Disclosed are a monoclonal antibody targeting domain 2 of ICAM-1 protein and a composition comprising the monoclonal antibody for treating or preventing T cell-mediated immune disease. The antibody of the present application induces antigen-specific T cell tolerance through the regulation of dendritic cell differentiation, and therefore, can be effectively used to treat or prevent autoimmune disease, organ or tissue transplant rejection, and graft-versus-host-disease.
1. A monoclonal antibody or an antigen-binding fragment thereof specific for human ICAM-1, the monoclonal antibody comprising: three complementary determining regions (CDRs) from the heavy chain of an antibody produced by the hybridoma cell deposited as accession number of KCLRF-BP-00264 or three CDRs from the light chain of an antibody produced by the hybridoma cell deposited as accession number of KCLRF-BP-00264, or both.
2. The antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody comprises two full length heavy chains and two full length light chains.
3. The antibody or the antigen-binding fragment thereof of claim 1 , wherein the antigen-binding fragment comprises SCV, ScFv, Fv, Fab, Fab′, or F(ab′) 2 .
4. The antibody or the antigen-binding fragment thereof of claim 1 , wherein the antibody or the antigen-binding fragment thereof is multi-valent or multi-functional.
5. The antibody or the antigen-binding fragment thereof of claim 1 , wherein the antibody or the antigen-binding fragment thereof is a multimer which is formed by two or more of the antibody or antigen-binding fragment thereof which is identical or different being linked to each other.
6. The antibody or the antigen binding fragment thereof of claim 1 , wherein the antibody or the antigen-binding fragment thereof is a chimeric form or a humanized form.
7. A method for treating a T-cell mediated immunological disorder or condition comprising administering to a subject in need thereof a pharmaceutical composition comprising the antibody or antigen binding fragment according to claim 1 .
8. The method of claim 7 , wherein the T-cell mediated immunological disorder or condition is a rejection of a tissue or an organ transplantation rejection, a graft-versus-host disease, or an autoimmune disease.
9. The method of claim 8 , wherein the tissue or the organ transplantation includes a pancreatic islet transplantation.
10. The method of claim 8 , wherein the tissue or the organ use for the transplantation is an allogenic or xenogenic origin.
11. The method of claim, wherein the pharmaceutical composition further comprises one or more immune regulatory agent selected from the group consisting of rapamycin, an anti-CD154 antibody, and an anti-CD40 antibody.
12. A method for producing an antibody specific for ICAM-1 comprising incubating a hybridoma cell deposited as accession number of KCLRF-BP-00264, and purifying the antibody.
13. A method for maintaining a dendritic cell in a semi-mature state comprising contacting the antibody or the antigen-binding fragment thereof according to claim 1 with an immature dendritic cells in vitro.